News Releases
- November 9, 2021Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
- November 2, 2021Annovis Bio to Present at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
- October 5, 2021Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson’s Disease
- September 24, 2021Annovis Bio to Present at the Cantor Global Healthcare Conference
- September 10, 2021Annovis Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
- September 3, 2021Annovis Bio Interview to Air on Bloomberg U.S. on the RedChip Money Report®
- August 25, 2021Annovis Bio to Present at Biomarkers for Alzheimer’s Disease Summit 2021
- August 11, 2021Annovis Bio Completes Dosing of Parkinson’s Disease Patients with ANVS401 in Phase 2a Clinical Trial
- July 30, 2021Annovis Bio Pleased by Positive Interim Results from Ongoing Phase II Clinical Trials of ANVS401 (Posiphen) for the Treatment of Alzheimer's Disease and Parkinson's Disease
- July 28, 2021Annovis Bio Presents New Clinical and Biomarker Data at 2021 Alzheimer's Association International Conference
Events & Presentations
-
Annovis Bio - Phase III PD Data
-
AD & PD Data Updates - July 2024
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top